1 Main

Case 1:15-cr-00637-KAM Document 1 Filed 12/14/15 Page 1 of 29 PageID #: 1
_,
- : -:1
JMK:WMP/AES
F. #2014R00501
MATSUMOTO, J.
UNITED STATES DISTRICT COURT

EASTERN DISTRICT OF NEW YORK
LEW, M.J.
-----------------------------X
UNITED STATES OF AMERICA
INDICTMENT
CB 15 -637
- against -
(T. 15, U.S.C., 78j(b) and 78ff;

T. 18, U.S.C., 371, 981 (a)(l )(C),
1349, 2 and 3551 et seq.; T. 21, U.S.C.,
853(p); T. 28, U.S.C., 246l(c))
MARTIN SHKRELI and

EVAN GREEBEL,
Defendants.
'"?)~":
_;;. !-f i
-----------------------------X
.:.c../>..... --1-:11;:.1
.. :~ ;1 (:.;
,;:.;:-~ 7:~!
INTRODUCTION
l"-:t
'-~
c..r:
,.,,
0
~~~~o
::;.::~g
CJ ....
At all times relevant to this Indictment, unless otherwise indicated: --; ~
("")~
('"')
---'.
~,~ :-;i-: ;o
--.;:o(=;
-< ;-;;--i
THE GRAND JURY CHARGES:
I.
-~~a
r-rrir
-0
:x
~
(...,)
Ul
The Defendants and Relevant Entities

1.
The defendant MARTIN SHKRELI was a resident of Brooklyn, New
York and New York, New York. From approximately 2006 to 2007, SHKRELI served as the
managing member and portfolio manager of El ea Capital Management ("Elea Capital"), a hedge
fund located in New York, New York. From approximately September 2009 to December 2012,
SHKRELI served as the managing member and portfolio manager of MSMB Capital
Management LP ("MSMB Capital"), a hedge fund located in New York, New York, that focused
its investments in the healthcare sector. From approximately February 2011 to December 2012,
SHKRELI served as the managing member and portfolio manager for MSMB Healthcare LP
("MSMB Healthcare"), a hedge fund located in New York, New York, that focused its
investments in the healthcare sector. From approximately December 2012 to September 2014,
SHKRELI was the Chief Executive Officer of Retrophin, Inc. ("Retrophin" or "RTRX"), a
:~:n rt1
:;:;;;G
publicly traded biopharmaceutical company with its principal place of business in New York,
New York.
2.
The defendant EV AN GREEBEL was a resident of Scarsdale, New York,
and an attorney licensed to practice law in New York. From approximately December 2012 to
September 2014, GREEBEL was a partner in the New York office of Katten Muchin Rosenman
LLP and served as lead outside counsel to Retrophin.
3.
MSMB Capital was a Delaware limited partnership founded by the
defendant MARTIN SHKRELI and Co-Conspirator 1, an individual whose identity is known to

the Grand Jury, in or about September 2009. The securities offered to investors by MSMB
Capital were limited partner interests, and investors in the fund became limited partners (the
"Capital Limited Partners"). The sole general partner of MSMB Capital was MSMB Investors
LLC, a Delaware limited liability company, which was controlled by SHKRELI. MSMB Capital
Management LLC, a Delaware limited liability company controlled by SHKRELI, served as the
investment adviser to MSMB Capital.
4.
MSMB Healthcare was a Delaware limited partnership founded by the
defendant MARTIN SHKRELI in or about February 2011. The securities offered to investors by
MSMB Healthcare were limited partner interests, and investors in the fund became limited
partners (the "Healthcare Limited Partners"). The sole general partner of MSMB Healthcare was
MSMB Healthcare Investors LLC, a Delaware limited liability company, which was controlled
by SHKRELI. MSMB Healthcare Management LLC, a Delaware limited liability company
controlled by SHKRELI, served as the investment adviser to MSMB Healthcare.
5.
Retrophin LLC ("Retrophin LLC") was a Delaware limited liability
company founded by the defendant MARTIN SHKRELI in or about March 2011. At its
1'"
inception, Retrophin LLC focused on finding a_ cure for children who suffered from muscular
dystrophy.
6.
Retrophin was a Delaware corporation founded by the defendant
MARTIN SHKRELI in or about 2011. In or about December 2012, Retrophin became a

publicly traded company that traded under the ticker symbol RTRX on the Over-the-Counter
(OTC) markets. In or about January 2014, Retrophin began trading on the NASDAQ Global
Market under the ticker symbol RTRX. Retrophin was a biopharmaceutical company focused on
the discovery, acquisition, development and commercialization of drugs for the treatment of
debilitating and life-threatening diseases for which there are currently limited patient options.
II.
The Fraudulent Schemes

7.
In or about and between September 2009 and September 2014, the
defendant MARTIN SHKRELI, together with the defendant EVAN GREEBEL and others,
orchestrated three interrelated fraudulent schemes:
a.
a scheme to defraud investors and potential investors in MSMB
Capital by inducing them to invest in MSMB Capital through material misrepresentations and
omissions about, inter alia, the prior performance of the fund, its assets under management and
the retaining of an independent auditor and administrator; and then by preventing redemptions by
investors in MSMB Capital through material misrepresentations and omissions about, inter alia,
the performance of the fund and the misappropriation by SHKRELI and others of fund assets;
b.
a scheme to defraud investors and potential investors in MSMB
Healthcare by inducing them to invest in MSMB Healthcare through material misrepresentations

and omissions about, inter alia, the prior performance of the fund, its assets under management
and existing liabilities; and then by preventing redemptions by the investors through material

'I
misrepresentations and omissions about, inter alia, the perfonnance of the fund and the
misappropriation by SHKRELI and others of fund assets; and
c.
a scheme to defraud Retrophin by misappropriating Retrophin' s
assets through material misrepresentations and omissions in an effort to satisfy SHKRELI' s

personal and unrelated professional debts and obligations. Specifically, SHKRELI, assisted by
GREEBEL and others, defrauded Retrophin by causing it to: (i) transfer Retrophin shares to
MSMB Capital even though MS~B Capital never invested in Retrophin; (ii) enter into
settlement agreements with defrauded MSMB Capital and MSMB Healthcare investors to settle
liabilities owed by the MSMB Capital and MSMB Healthcare funds (the "MSMB Funds") and
SHKRELI; and (iii) enter into sham consulting-agreements with other defrauded MSMB Capital,
MSMB Healthcare and Elea Capital investors as an alternative means to settle liabilities owed by
the MSMB Funds and SHKRELI.
A.
The MSMB Capital Hedge Fund Scheme

8.
In or about and between September 2009 and December 2010, the
defendant MARTIN SHKRELI, together with Co-Conspirator 1, in an effort to induce

investments in MSMB Capital, represented to potential investors, inter alia, that: (i) MSMB
Capital was a transparent investment vehicle for sophisticated investors with monthly liquidity;
(ii) the investment adviser was entitled to receive a one percent management fee per year based
on net assets of the partnership; (iii) the general partner was entitled to receive twenty percent of
the limited partners' net profits for the year; and (iv) MSMB Capital had retained independent
certified public accountants as auditors who would issue an audit report on the annual financial
statements. Based on these representations and additional representations about SHKRELI's
success as a portfolio manager and personal investment in the fund, from approximately

I
September 2009 through November 2010, SHKRELI, together with Co-Conspirator I, induced
investments of approximately $700,000 from a total of four Capital Limited Partners. In fact,
MSMB Capital did not retain an independent auditor, was not transparent and did not have the
necessary monthly liquidity to satisfy large redemption requests. Additionally, SHKRELI failed
to disclose to the Capital Limited Partners that he had lost all the money he managed in Elea
Capital, his prior hedge fund, and that there was a $2.3 million default judgment against him
from Lehman Brothers resulting from his tradi~g activity.
9.
In approximately December 2010 and January 2011, the defendant
MARTIN SHKRELI, together with others, continued to induce investments in MSMB Capital
based on material misrepresentations and omissions. On or about December 2, 20 I 0, Investor 1,
a Capital Limited Partner whose identity is known to the Grand Jury and whom SHKRELI had
been encouraging to invest in MSMB Capital since early 2010, asked SHKRELI in an email
about, inter alia, the fund's assets under management and the names of its independent auditor
and fund administrator. SHKRELI told Investor I that MSMB Capital had $35 million in assets
under management and that the fund's independent auditor and administrator were Rothstein,
Kass & Company, P.C. ("Rothstein Kass") and NAV Consulting Inc. ("NAV Consulting"),
respectively. At the time of this representation, MSMB Capital did not have an independent
auditor or administrator, and SHKRELI had lost through trading the approximately $700,000 that
had been invested by the four Capital Limited Partners. In fact, as of November 30, 2010, the
value of assets in MSMB Capital's bank and brokerage accounts totaled approximately $700.
10.
In reliance on the defendant MARTIN SHKRELI's material
misrepresentations and omissions, on or about December 8, 20 I 0, Investor 1 sent $1,000,000 by

wire transfer to MSMB Capital's brokerage account. Approximately one month later, on or
about January 5, 2011, Investor 1 sent $250,000 by wire transfer to MSMB Capital's brokerage
account. In approximately January 2011, three additional individuals invested approximately
$1,000,000 in MSMB Capital based on SHKRELI's material misrepresentations and omissions.
In sum, eight investors, whose identities are known to the Grand Jury, invested a total of
approximately $3 million in MSMB Capital.
11.
On or about February 1, 2011, the defendant MARTIN SHKRELI took a
large short sale position in Orexigen Therapeutics, Inc. ("OREX") in MSMB Capital's brokerage
account at Merrill, Lynch, Pierce, Fenner & Smith, Incorporated ("Merrill Lynch"). Specifically,
SHKRELI sold short over 32 million shares of OREX. Contrary to SHKRELI' s representations
to Merrill Lynch, MSMB Capital had failed to locate OREX shares to borrow in order to settle
MSMB Capital's short sales. As a result, MSMB Capital failed to settle a short position of over
11 million shares of OREX, which Merrill Lynch ultimately closed at a loss of over $7 million.
In addition to the losses in the Merrill Lynch account, MSMB Capital suffered over $1 million in
other trading losses in approximately February 2011. Based on these trading losses, the value of
assets in MSMB Capital's bank and brokerage accounts, not including the OREX losses at
Merrill Lynch, declined from more than $1.12 million on or about January 31, 2011 to $58,500
at the end of February 2011. MSMB Capital did not engage in any trading after February 2011.
12.
In furtherance of the scheme of defraud, the defendant MARTIN
SHKRELI concealed MSMB Capital's true performance from the Capital Limited Partners. For
months following the complete loss of the investments in MSMB Capital and the end of trading
activity, SHKRELI continued to send fabricated performance updates to the Capital Limited
Partners that touted profits of as high as forty percent since inception. For example, on or about
April 10, 2011, SHKRELI sent an email to Investor 2, a Capital Limited Partner whose identity
'
is known to the Grand Jury, informing him that MSMB Capital had returned a profit of 8.93
percent since the beginning of the year and a profit of 42.57 percent since inception on
November 1, 2009. SHKRELI also informed Investor 2, who had first invested in MSMB
Capital on or about November 1, 2009, that his.total investment of $400,000 was now
approximately $509,514. Similarly, on or about January 25, 2012, almost one year after MSMB
Capital had ceased trading and lost all its assets, SHKRELI informed Investor 1 that his total
investment of $1,250,000 was now "approximately $1,318,872, net of fees."
13.
The defendant MARTIN SHKRELI, together with Co-Conspirator 1, also
misappropriated funds from MSMB Capital by withdrawing funds from MSMB Capital that
were far in excess of the one percent management fee and the twenty percent net profit incentive
allocation permitted by the partnership agreement. Specifically, without the Capital Limited
Partners' knowledge or consent, SHKRELI withdrew and spent more than $200,000 from
MSMB Capital during the life of the fund, which was far in excess of any permitted fees.
14.
On or about September 5, 2012, the defendant MARTIN SHKRELI, Co-
Conspirator 1 and MSMB Capital entered into a settlement agreement with Merrill Lynch to
resolve a Financial Industry Regulatory Authority, Inc. ("FINRA") arbitration proceeding in
connection with the OREX trading losses of approximately $7 million. Pursuant to the
settlement with Merrill Lynch, SHKRELI, Co-Conspirator 1 and MSMB Capital agreed to pay
Merrill Lynch a total of $1,350,000 on or before December 15, 2012. Notably, in the settlement
agreement, SHKRELI and Co-Conspirator 1 admitted that MSMB Capital had $0 in assets.
15.
On or about September 10, 2012, a mere five days after the defendant
MARTIN SHKRELI and Co-Conspirator 1 admitted that MSMB Capital had no assets,
SHKRELI sent an email (the "Liquidation Email") to the Capital Limited Partners, including
',
Investor 2, and stated, in part: '"I have decided ~o wind down our hedge fund partnerships with a
goal of completing the liquidation of the funds by November or December 1st, 2012 ... .
Original MSMB investors (2009) have just about doubled their money net of fees .... investors
will have their limited partnership interests redeemed by the fund for cash. Alternatively,
investors may ask for a redemption of Retrophin shares, or a combination of Retrophin shares
and cash." Contrary to SHKRELI's representations: (i) the MSMB Capital investors who
invested in 2009 had lost their investments, not "doubled their money net of fees"; and (ii)
SHKRELI had not yet fulfilled a redemption request by Investor 1, who had made the request in
or about November 2011.
B.
The MSMB Healthcare Hedge Fund Scheme

16.
Following the collapse ofMSMB Capital after the failed OREX trade,
from approximately February 2011 to November 2012, the defendant MARTIN SHKRELI,
together with others, solicited investments in MSMB Healthcare from potential investors based
on material misrepresentations and omissions about, inter alia, SHKRELI' s past performance as
a portfolio manager. Specifically, SHKRELI and his co-conspirators concealed from potential
investors SHKRELI' s disastrous past performance as a portfolio manager for MSMB Capital and
Elea Capital and the $7 million liability that SHKRELI owed Merrill Lynch for the February
2011 OREX trades. For example, on or about April 7, 2011, Investor 3, a Healthcare Limited
Partner whose identity is known to the Grand Jury, invested $1,000,000 in MSMB Healthcare
following telephone conversations and meetings with SHKRELI and Corrupt Employee 1, an
individual employed by SHKRELI whose identity is known to the Grand Jury, during which
Investor 3 was provided with only positive information about SHKRELI, was never informed of
SHKRELI' s performance with MSMB Capital and Elea Capital and was never informed about
"
SHKRELI' s liability to Merrill Lynch. In sum, thirteen individuals invested a total of

approximately $5 million in MSMB Healthcare.
17.
In furtherance of the scheme to defraud, the defendant MARTIN
SHKRELI made material misrepresentations to potential investors about MSMB Healthcare's

assets under management. For example, on or about April 18, 2012, in response to an inquiry by
a potential investor, SHKRELI informed Corrupt Employee 1 to tell the potential investor that
MSMB Healthcare had $55 million in assets under management. At no point, from inception to
liquidation, did the total amount of investments in MSMB Healthcare exceed $6 million.
18.
The defendant MARTIN SHKRELI also made material misrepresentations
to the Healthcare Limited Partners in an effort to prevent them from seeking redemption of their
investments in MSMB Healthcare. In fact, on or about September 10, 2012, SHKRELI also sent
the Liquidation Email to the Healthcare Limited Partners, including Investor 3. Contrary to
SHKRELI's representations: (i) the original MSMB Capital investors who invested in 2009 had
lost their investments, not "doubled their money net of fees"; and (ii) MSMB Healthcare did not
have the necessary funds to have its limited partners redeem their investments for cash.
19.
The defendant MARTIN SHKRELI, together with others, also
misappropriated funds from MSMB Healthcare by withdrawing funds from MSMB Healthcare
that were far in excess of the one percent management fee permitted by the partnership
agreement and the twenty percent net profit incentive allocation afforded to the general partner
of the fund. Additionally, without the Healthcare Limited Partners' knowledge or consent,
SHKRELI improperly used MSMB Healthcare assets to pay for obligations that were not the
responsibility of MSMB Healthcare. For example, SHKRELI caused assets from MSMB
Healthcare to be used to pay money owed by MSMB Capital, SHKRELI and Co-Conspirator 1
to settle claims brought by Merrill Lynch in connection with the failed OREX trades.
20.
To achieve this fraudulei:it objective, in or about November 2012, the
defendant MARTIN SHKRELI improperly reclassified a $900,000 equity investment by MSMB

Healthcare in Retrophin LLC as an interest-bearing loan through the use of a backdated
promissory note, thereby causing 22,500 Retrophin LLC shares that had been issued to MSMB
Healthcare at the time of the equity investment to be deleted from Retrophin LLC' s
capitalization table. A capitalization table is a record of all the major shareholders of a company,
along with their pro-rata ownership of all the securities issued by the company (equity shares,
preferred shares and options), and the various prices paid by these stakeholders for these
securities. On or about January 18, 2013, SHKRELI caused Retrophin, the publicly traded
company, to transfer $150,000 into MSMB Healthcare's bank account as partial payment of the
improperly reclassified loan, $125,000 of which he wire transferred to Merrill Lynch to get an
extension for a settlement payment owed by MSMB Capital, SHKRELI and Co-Conspirator 1.
Finally, on or about March 4, 2012, SHKRELI caused Retrophin to transfer $773,000 into
MSMB Healthcare's bank account as the remaining repayment of the "loan," which amount he
then wire transferred that same day to Merrill Lynch to satisfy the debt owed to Merrill Lynch by
SHKRELI, Co-Conspirator 1 and MSMB Capital pursuant to the OREX trade settlement.
C.
The Retrophin Misappropriation Scheme

21.
The defendants MARTIN SHKRELI and EVAN GREEBEL, together
with others, engaged in a scheme to defraud Retrophin by misappropriating Retrophin' s assets

through material misrepresentations and omissi.ons in an effort to satisfy SHKRELI' s personal
and unrelated professional debts and obligations. Specifically, SHKRELI, assisted by
10
'
'
GREEBEL and others, defrauded Retrophin by causing it to: (i) transfer Retrophin shares to
MSMB Capital even though MSMB Capital never invested in Retrophin; (ii) enter into
settlement agreements with defrauded MSMB Capital and MSMB Healthcare investors to settle
liabilities owed by the MSMB Funds and SHKRELI; and (iii) enter into sham consulting
agreements with other defrauded MSMB Capital, MSMB Healthcare and Elea Capital investors
as an alternative means to settle liabilities owed by the MSMB Funds and SHKRELI.
(i).
The Fabricated MSMB Capital Interest
22.
In or about March 2011, the defendant MARTIN SHKRELI valued
Retrophin LLC as a $20 million company based on 100,000 outstanding shares and SHKRELI' s
valuation that each share or unit was worth $200, even though Retrophin LLC had no products or
assets. In 2011 and 2012, SHKRELI began using MSMB Healthcare funds to invest in
Retrophin LLC and solicited investments in Retrophin LLC, including additional investments
from Capital Limited Partners and Healthcare Limited Partners who had been misled by
SHKRELI and others that their investments were performing exceptionally well. These
investments were recorded on Retrophin LLC's capitalization table.
23.
As of July 31, 2012, Retrophin LLC's capitalization table, which was
reviewed by the defendants MARTIN SHKRELI and EVAN GREEBEL, among others, revealed
that MSMB Healthcare had invested approximately $2,135,000 in Retrophin LLC. The records
did not reflect any investments by MSMB Capital. Similarly, as of September 5, 2012, the
capitalization table, which was reviewed by SHKRELI and GREEBEL, among others, revealed
approximately $5 million in investments in Retrophin LLC, but no investments by MSMB
Capital. On or about November 14, 2012, Accounting Firm 1, which was retained by Retrophin
LLC to review its books and records, was provjded an updated capitalization table that revealed
11
approximately $4.75 million in investments in Retrophin LLC, but no investments by MSMB

Capital.
24.
In or about November 2012, the defendant MARTIN SHKRELI
responded to inquiries by the United States Securities and Exchange Commission ("SEC") about
his management of MSMB Capital and MSMB Healthcare. On or about November 4, 2012,
SHKRELI sent an email to the SEC, in which he stated, in part: "We have decided to end the
MSMB limited partnerships ... limited partners have been notified of the plans for the
redemption of assets." SHKRELI then grouped the MSMB Funds together and stated that
Retrophin LLC was the "most successful and largest effort" of the MSMB group of funds, which
included MSMB Capital. Additionally, SHKRELI claimed that MSMB Capital was still active,
had $2,600,000 in assets under management and was in the process of being liquidated.
Contrary to these representations, MSMB Capital had essentially no assets following the
February 2011 OREX trades and was in debt to Merrill Lynch.
25.
Faced with an SEC inquiry, the defendants MARTIN SHKRELI and
EV AN GREEBEL, together with others, engaged in a scheme to fabricate an investment by

MSMB Capital in Retrophin LLC and engineered a series of fraudulent transactions that were
backdated to the summer of 2012 to create the appearance of an investment by MSMB Capital
prior to the SEC inquiry. Specifically, in or about November and December 2012, SHKRELI
and GREEBEL orchestrated a transfer of shares to SHKRELI from Co-Conspirator 1, as well as
Corrupt Employee 1 and Corrupt Employee 2, individuals whose identities are known to the
Grand Jury, and backdated them to the summer of 2012. SHKRELI then immediately
transferred, also pursuant to a backdated agreement, 75,000 shares to MSMB Capital that he
received from Co-Conspirator 1, Corrupt Employee 1 and Corrupt Employee 2. SHKRELI and
12
GREEBEL, together with others, convinced Co-Conspirator 1, Corrupt Employee 1 and Corrupt
Employee 2 to transfer their Retrophin LLC shares to SHKRELI by enticing them with the
opportunity to acquire, for a nominal amount, approximately five percent of the unrestricted or
free trading shares ofRetrophin, the publicly traded company that SHKRELI was in the process
of creating through a reverse merger. The following series of emails provides a glimpse into the
scheme perpetrated by SHKRELI and GREEBEL:
a.
On or about November 20, 2012, GREEBEL provided RTRX
Employee 1, an individual whose identity is known to the Grand Jury, with a template share
transfer agreement that he had previously provided to SHKRELI.
b.
On or about November 25, 2012, in response to an inquiry from
SHKRELI about cancelling a transfer of Retrophin shares previously given by SHKRELI,

GREEB EL responded, "hard to unwind stuff - easier if they transfer back."
c.
On or about November 29, 2012, at 3:20 p.m., RTRX Employee 1
sent an email to GREEBEL, and Accountant 1 and Accountant 2, whose identities are known to
the Grand Jury, and attached an agreement that transferred 4,167 shares from Co-Conspirator 1
to SHKRELI. The agreement was signed by SHKRELI and Co-Conspirator 1 and dated
November 29, 2012.
d.
On or about November 29, 2012, between 3:29 p.m. and 3:46 p.m.,
SHKRELI, GREEBEL, Co-Conspirator 1 and RTRX Employee 1 exchanged emails where

SHKRELI stated, "that agreement was signed in June." Notably, GREEBEL removed the
outside accountants for this email exchange.
e.
A few minutes later, at 3:55 p.m., RTRX Employee 1 sent an email
to SHKRELI and GREEBEL, copying Co-Conspirator 1, and attached the same transfer
13
"
agreement, with one change: the November 29, 2012 dates below the signature lines for
SHKRELI and Co-Conspirator 1 were covered by clearly visible redacting tape and replaced
with a date of July 1, 2012.
f.
One minute later, in response to the email sent by RTRX
Employee 1, GREEBEL sent an email to RTRX Employee 1 and stated, "please call me."
g.
Amidst this email exchange, at 4:04 p.m., Accountant 1, who had
received the original share transfer agreement from RTRX Employee 1, exclaimed, "WT .... F."
h.
At 4:32 p.m., approximately thirty minutes after GREEBEL asked
RTRX Employee 1 to call him, RTRX Employee 1 sent an email to SHKRELI and GREEBEL,
copying Co-Conspirator 1, and attached the transfer agreement between SHKRELI and CoConspirator 1. This version, however, had a new signature page without any visible redacting
tape and a new date, June 1, 2012, was typed, rather than handwritten.
1.
On or about Dec~mber 3, 2012, RTRX Employee 1 sent
Accountant 1 an email attaching Co-Conspirator 1's backdated agreement, similar backdated

share transfer agreements executed by Corrupt Employee 1 and Corrupt Employee 2, both dated
July l, 2012, and an agreement between SHKRELI and MSMB Capital, dated July 1, 2012,
transferring 75,000 shares from SHKRELI to MSMB Capital. Notably, although each of these
agreements reflects a date in the summer of 2012, none of the transfers in the agreements are
reflected in the capitalization tables that were prepared in July, September and November 2012.
J.
A few hours later, SHKRELI sent an email to GREEBEL and
RTRX Employee 1 and attached the "final.capitalization table," which contained an entry for
MSMB Capital for 75,000 shares.
14
(ii).
The Fraudulent Settlement Agreements
26.
In or about and between February 2013 and August 2013, the defendants
MARTIN SHKRELI and EV AN GREEB EL, together with others, caused Retrophin to enter into
settlement agreements with three Capital Limited Partners and four Healthcare Limited Partners
to resolve claims and threats of claims made by the limited partners against SHKRELI and
MSMB Capital or MSMB Healthcare. SHKRELI and GREEBEL, who were present at all
relevant Retrophin Board of Directors (the "Board") meetings, did not seek authorization from
the Board prior to entering into these fraudulent settlements.
27.
The defendants MARTIN SHKRELI and EVAN GREEBEL engaged in
this scheme to defraud Retrophin of its assets in an effort to conceal the material
misrepresentations that SHKRELI made to the three Capital Limited Partners and four
Healthcare Limited Partners about, inter alia, performance and liquidity. For example, on or
about September 10, 2012, SHKRELI had falsely represented to the three Capital Limited
Partners, whose identities are known to the Grand Jury, that their investments had returned
profits ranging from 41.12 percent to 79.49 percent. Similarly, on or about September 9, 2012,
SHKRELI had falsely represented to the four Healthcare Limited Partners that their investments
had returned profits ranging from 15.58 percent to 34.48 percent. The next day, in the
Liquidation Email, SHKRELI had informed the limited partners of MSMB Capital and MSMB
Healthcare that he was winding down the funds and that they could have their interests redeemed
by the fund for cash. Contrary to these representations, MSMB Capital had ceased operating in
February 2011 and all investments by the Capital Limited Partners had been lost following the
February 2011 OREX trades. Similarly, SHKRELI's performance updates to the Healthcare
15
Limited Partners were false because they were based on an internal, inflated valuation of
Retrophin, and MSMB Healthcare did not have liquid assets to fulfill cash redemptions.
28.
In sum, the defendants MARTIN SHKRELI and EVAN GREEBEL,
together with others, caused Retrophin to pay more than $3.4 million in cash and RTRX stock to
settle claims with the seven Capital Limited Partners and Healthcare Limited Partners even
though Retrophin was not responsible for those claims.
29.
In or about August 2013, Retrophin's external auditor questioned the
settlement agreements that had been as of that time and determined that Retrophin was not
responsible for the claims resolved in the settlement agreements. Consequently, Retrophin's
public filings had to be restated and amended. On or about August 23, 2013, the defendants
MARTIN SHKRELI and EVAN GREEBEL discussed the impact of the auditor's determination
in a lengthy email exchange. When SHKRELI suggested that the old agreements should be
annulled, GREEBEL responded that the auditor "didn't like that idea." When SHKRELI then
admitte~
that "there were serious faults with the [settlement] agreements including lack of board
approval" and that redoing the settlement agreements may be a good idea, GREEBEL responded:
"That will open up some very big issues. The current thinking is let rtrx pay, get a note from the
fund[,] and if the fund cant [sic] fulfill the note[,] rtrx will write it off as a bad debt. It would be
easier than the road you are referring to. Also, [the auditor] would get very spooked with what
you are talking about (which could also spook your investors and counter parties)." In response,
SHKRELI stated, "[o]n current thinking: that works for me."
30.
A few days later, the defendants MARTIN SHKRELI and EVAN
GREEBEL caused MSMB Capital and MSMB Healthcare to execute indemnification

agreements and promissory notes for the benefit of Retrophin even though they knew that the
16
MSMB Funds had no assets. In furtherance of the scheme, SHKRELI and GREEB EL assured
Retrophin and the auditors that the promissory notes would be repaid. Retrophin was never
indemnified for these fraudulent settlement agreements.
(iii).
The Sham Consulting Agreements
31.
After Retrophin' s external auditors had determined that Retrophin was not
responsible for the claims settled in the settlement agreements, the defendants MARTIN
SHKRELI and EV AN GREEBEL, together with others, devised an alternative approach to settle
with defrauded limited partners from SHKRELI' s hedge funds: settlement agreements under the
guise of consulting agreements. SHKRELI and GREEBEL's fraudulent scheme is evident in an
email exchange on or about October 16, 2013. Initially, GREEBEL sent an email to SHKRELI
informing him that Investor 1 wanted 100,000 RTRX shares as part of his settlement and did not
want to enter into a consulting agreement. When SHKRELI indicated that the proposal was
acceptable to him, GREEBEL stated, "Where will the lOOk come from? If it's from the
company it would need to be in a consulting agreement." SHKRELI questioned GREEBEL's
approach and stated, "Why would it need to be a consulting agreement???! Have you heard of
the term settlement?" In response, GREEBEL explained, "We can call it a settlement agreement,
but given [the auditor's] recent behavior they may require it to be disclosed in the financials. I
was trying to prevent that issue."
32.
In or about and between September 2013 and March 2014, the defendants
MARTIN SHKRELI and EV AN GREEBEL, together with others, caused Retrophin to enter into
four sham consulting agreements with defrauded investors from Elea Capital, MSMB Capital
and MSMB Healthcare to resolve claims and threats of claims by those investors against
SHKRELI and the MSMB Funds. Three of the four sham consulting agreements, which
17
"
included agreements with Investor 1 and Investor 3, provided that the defrauded investors would
provide consulting services "on strategic and c9rporate governance matters to the management of
the company" and contained releases as to, inter alia, SHKRELI, the MSMB Furids and
Retrophin. The fourth sham consulting agreement, which was entered into with the defrauded
Elea Capital investor, provided that the investor would provide consulting services "on cluster
headache drug development and other matters to the Company" but did not include any releases.
Retrophin did not receive any legitimate consulting services based on these sham agreements.
33.
The defendants MARTIN SHKRELI and EV AN GREEBEL, who were
present at all relevant Board meetings, never presented three of the four sham consulting
agreements to the Board for approval, and although the consulting agreement with Investor 3
was placed on the Board's agenda, it was never approved. Additionally, SHKRELI and
GREEB EL concealed from the Board that the purpose of that consulting agreement was to
resolve Investor 3's complaints about his MSMB Healthcare investment. As another example of
the scheme to conceal the true nature of the sham consulting agreements, on or about April 19,
2013, GREEBEL sent an email to SHKRELI attaching a form consulting agreement to use to
settle claims with Investor 3, and stated, in part: "I think you should get blanket approval from
the board for you to retain consultants who may be paid in cash or stock up to an aggregate
amount of$."
34.
As with the settlement agreements, the defendants MARTIN SHKRELI
and EVAN GREEBEL, together with others, devised the sham consulting agreements to conceal
the material misrepresentations that SHKRELI .made to the Capital Limited Partners and
Healthcare Limited Partners about, inter alia, performance and liquidity. For example, on or
about January 25, 2012, in the last performance update provided to Investor 1, SHKRELI falsely
.18
represented to Investor 1 that his investment had returned a profit of 5.51 percent. Similarly, on
or about September 9, 2012, SHKRELI falsely represented to Investor 3 and another Healthcare
Limited Partner that their investments had returned profits of 34.48 percent and 9.75 percent,
respectively. The next day, in the Liquidation Email, SHKRELI informed the limited partners of
MSMB Capital and MSMB Healthcare that he was winding down the funds and that they could
have their interests redeemed by the fund for cash. Contrary to these representations, MSMB
Capital had been defunct since February 2011 and all investments by the Capital Limited
Partners had been lost following the February 2011 OREX trades. Similarly, SHKRELI's
performance updates to the Healthcare Limited Partners were false because they were based on
an internal, inflated valuation of Retrophin, and MSMB Healthcare did not have liquid assets to
fulfill cash redemptions.
35.
In sum, the defendants MARTIN SHKRELI and EV AN GREEBEL,
together with others, caused Retrophin to pay more than $7.6 million in cash and RTRX stock
through sham consulting agreements to settle claims with Capital Limited Partners and
Healthcare Limited Partners even though Retrophin was not responsible for those claims.
COUNT ONE
(Conspiracy to Commit Securities Fraud- MSMB Capital Scheme)
36.
The allegations contained in paragraphs one through thirty-five are
realleged and incorporated as though fully set forth in this paragraph.

37.
In or about and between September 2009 and September 2014, both dates
being approximate and inclusive, within the Eastern District of New York and elsewhere, the
defendant MARTIN SHKRELI, together with others, did knowingly and willfully conspire to
use and employ manipulative and deceptive devices and contrivances, contrary to Rule 1Ob-5 of
19
.'
the Rules and Regulations of the United States Securities and Exchange Commission, Title 17,
Code of Federal Regulations, Section 240.lOb-5, by: (a) employing devices, schemes and
artifices to defraud; (b) making untrue statements of material fact and omitting to state material
facts necessary in order to make the statements_ made, in light of the circumstances under which
they were made, not misleading; and (c) engaging in acts, practices and courses of business
which would and did operate as a fraud and deceit upon investors and potential investors in
MSMB Capital, in connection with the purchase and sale of investments in MSMB Capital,
directly and indirectly, by use of means and instrumentalities of interstate commerce and the
mails, contrary to Title 15, United States Code, Sections 78j(b) and 78ff.
38.
In furtherance of the conspiracy and to effect its objects, within the
Eastern District of New York and elsewhere, the defendant MARTIN SHKRELI, together with
others, committed and caused to be committed," among others, the following:
OVERT ACTS
a.
On or about October 24, 2009, Co-Conspirator 1 sent an email to
Investor 2, a Capital Limited Partner whose identity is known to the Grand Jury, copying
SHKRELI and enclosing the "MSMB Capital Investor Kit," which included a presentation and a
private placement memorandum.
b.
On or about February 18, 2010, SHKRELI sent an email to the
Capital Limited Partners, including Investor 2, and stated, in part: "Our fund is open to new and
additional investments. Our terms are 1%/20% fees with monthly liquidity."
c.
On or about June 9, 2010, SHKRELI sent an email to Investor 1, a
Capital Limited Partner whose identity is known to the Grand Jury, attaching MSMB Capital
documents, and stated, in part: "The fund is a 1/20 fee structure with no lock-ups .... we have a
20
daily results email some people like to see ... hedge fund performance should be easy enough to
report/calculate estimates on a daily basis, and it is .... I'd love to have you as an investor- it
looks like we see eye-to-eye on a number of topics."
. d.
On or about October 6, 2010, SHKRELI sent an email to the
Capital Limited Partners, including Investor 2, and attached a letter entitled "MSMB Capital
Management Limited Partnership Letter for Q3 2010." In the letter, SHKRELI stated, in part,
that the "partnership performed well, returning 9% in Q3 201 O" and that brought the "gross yearto-date return to 44%."
e.
On or about December 2, 2010, SHKRELI sent an email to
Investor 1, and stated, in part, that MSMB Capital's current assets under management were $35
million, its auditor was Rothstein Kass, and its administrator was NAV Consulting.
f.
On or about January 3, 2011, SHKRELI sent an email to the
Capital Limited Partners, including Investor 2, and stated that MSMB Capital had "returned
+30.44% in 2010" and "+30.97% since inception on 11/1/2009."
g.
On or about February 2, 2011, SHKRELI sent an email to Co-
Conspirator 1 and an employee and attached a spreadsheet detailing MSMB Capital's OREX
trading.
h.
On or about February 9, 2011, SHKRELI sent an email to the
Capital Limited Partners, including Investor 1 and Investor 2, and stated that MSMB Capital had
"returned +3.80% gross of fees year-to-date" and "+35.95% since inception on 11/1/2009."
i.
On or about November 17, 2011, Investor 1 sent a letter to
SHKRELI providing written notice of a request for a full withdrawal of his investment in MSMB
Capital based on the fund's net asset value as ofNovember 30, 2011.
21
J.
On or about January 25, 2012, SHKRELI sent an email to Investor
1, copying others, and stated, in part: "You invested $1,250,000 for the 12/3112010 period. The
value of this investment is now approximately $1,318,872, net of fees ... We acknowledge your
redemption and this will be your last statement."
k.
On or about September 10, 2012, SHKRELI sent an email to the
Capital Limited Partners, including Investor 2, ~d stated, in part: "I have decided to wind down
our hedge fund partnerships with a goal of completing the liquidation of the funds by November
or December 1st, 2012 .... Original MSMB investors (2009) have just about doubled their
money net of fees .... investors will have their limited partnership interests redeemed by the
fund for cash. Alternatively, investors may ask for a redemption of Retrophin shares, or a
combination of Retrophin shares and cash."
(Title 18, United States Code, Sections 371 and 3551 et seq.)
COUNT TWO
(Conspiracy to Commit Wire Fraud - MSMB Capital Scheme)
39.

40.
defendant MARTIN SHKRELI, together with others, did knowingly and intentionally conspire
to devise a scheme and artifice to defraud investors and potential investors in MSMB Capital,
and to obtain money and property from them by means of materially false and fraudulent
pretenses, representations and promises, and for the purpose of executing such scheme and
artifice, to transmit and cause to be transmitted by means of wire communication in interstate
22
and foreign commerce writings, signs, signals, pictures and sounds, contrary to Title 18, United
States Code, Section 1343.
COUNT THREE
(Securities Fraud - MSMB Capital Scheme)
41.

42.
defendant MARTIN SHKRELI, together with others, did knowingly and willfully use and
employ one or more manipulative and deceptive devices and contrivances, contrary to Rule 1Ob5 of the Rules and Regulations of the United States Securities and Exchange Commission, Title
17, Code of Federal Regulations, Section 240.lOb-5, by: (a) employing one or more devices,
schemes and artifices to defraud; (b) making one or more untrue statements of material fact and
omitting to state one or more material facts necessary in order to make the statements made, in
light of the circumstances in which they were made, not misleading; and (c) engaging in one or
more acts, practices and courses of business which would and did operate as a fraud and deceit
upon one or more investors or potential investors in MSMB Capital, in connection with the
purchase and sale of investments in MSMB Capital, directly and indirectly, by use of means and
instrumentalities of interstate commerce and the mails.
(Title 15, United States Code, Sections 78j(b) and 78ff; Title 18, United States
Code, Sections 2 and 3551 et seq.)
23
COUNT FOUR
(Conspiracy to Commit Securities Fraud - MSMB Healthcare Scheme)
43.

44.
In or about and between February 2011 and September 2014, both dates
defendant MARTIN SHKRELI, together with others, did knowingly and willfully conspire to
use and employ manipulative and deceptive devices and contrivances, contrary to Rule 1Ob-5 of
the Rules and Regulations of the United States Securities and Exchange Commission, Title 17,
Code of Federal Regulations, Section 240.lOb-5, by: (a) employing devices, schemes and
artifices to defraud; (b) making untrue statements of material fact and omitting to state material
facts necessary in order to make the statements made, in light of the circumstances under which
they were made, not misleading; and (c) engaging in acts, practices and courses of business
which would and did operate as a fraud and deceit upon investors and potential investors in
MSMB Healthcare, in connection with the purchase and sale of investments in MSMB
Healthcare, directly and indirectly, by use of m~ans and instrumentalities of interstate commerce
and the mails, contrary to Title 15, United States Code, Sections 78j(b) and 78ff.
45.
In furtherance of the conspiracy and to effect its objects, within the
Eastern District of New York and elsewhere, the defendant MARTIN SHKRELI, together with
others, committed and caused to be committed; among others, the following:
OVERT ACTS
a.
On or about December 16, 2011, SHKRELI sent an email to
Corrupt Employee 1, an individual employed by SHKRELI whose identity is known to the
24
Grand Jury, and stated that MSMB Healthcare had $45 million in assets under management, and
$80 million in assets under management if the full value of Retrophin was taken into account.
b.
On or about January 24, 2012, in response to an email from
Investor 3, a Healthcare Limited Partner whose identity is known to the Grand Jury, who had
expressed concerned about MSMB Healthcare's performance, SHKRELI stated: "The real loss is
-2% and 2% will be added to December - we negotiated hard with accountants to represent -2%
but time constraints resulted in us printing -4%."
c.
On or about April 18, 2012, SHKRELI sent an email to Corrupt
Employee 1, and stated that MSMB Healthcare had $55 million in assets under management.
d.
On or about April 19, 2012, in response to an inquiry by a potential
sophisticated investor about how MSMB Healtticare could pay employee salaries with a modest
asset base of $55 million, SHKRELI stated: "Lots of ways - many of us have zero salaries or
low salaries. We have some expenses the fund pays for and yet other deferments that are
creative. Will tell more when we meet!"
e.
On or about September 10, 2012, SHKRELI sent an email to the
Healthcare Limited Partners, including Investor 3, and stated, in part: "I have decided to wind
down our hedge fund partnerships with a goal of completing the liquidation of the funds by
November or December 1st, 2012 .... Original MSMB investors (2009) have just about doubled
their money net of fees .... investors will have.their limited partnership interests redeemed by
the fund for cash. Alternatively, investors may ask for a redemption of Retrophin shares, or a
combination of Retrophin shares and cash."
{Title 18, United States Code, Sections 371 and 3551 et seq.)
25
COUNT FIVE
(Conspiracy to Commit Wire Fraud-MSMB Healthcare Scheme)
46.

47.
defendant MARTIN SHKRELI, together with others, did knowingly and intentionally conspire
to devise a scheme and artifice to defraud investors and potential investors in MSMB Healthcare,
and to obtain money and property from them by means of materially false and fraudulent
pretenses, representations and promises, and for the purpose of executing such scheme and
artifice, to transmit and cause to be transmitted by means of wire communication in interstate
and foreign commerce writings, signs, signals, pictures and sounds, contrary to Title 18, United
States Code, Section 1343.
COUNT SIX
(Securities Fraud - MSMB Healthcare Scheme)
48.

49.
defendant MARTIN SHKRELI, together with others, did knowingly and willfully use and
employ one or more manipulative and deceptive devices and contrivances, contrary to Rule 1Ob5 of the Rules and Regulations of the United States Securities and Exchange Commission, Title
17, Code of Federal Regulations, Section 240.lOb-5, by: (a) employing one or more devices,
26
schemes and artifices to defraud; (b) making one or more untrue statements of material fact and
. omitting to state one or more material facts nec.essary in order to make the statements made, in
light of the circumstances in which they were made, not misleading; and (c) engaging in one or
more acts, practices and courses of business which would and did operate as a fraud and deceit
upon one or more investors or potential investors in MSMB Healthcare, in connection with the
purchase and sale of investments in MSMB Healthcare, directly and indirectly, by use of means
and instrumentalities of interstate commerce and the mails.
(Title 15, United States Code, Sections 78j(b) and 78ff; Title 18, United States
Code, Sections 2 and 3551 et seq.)
COUNT SEVEN
(Conspiracy to Commit Wire Fraud-Retrophin Scheme)
50.

51.
defendants MARTIN SHKRELI and EV AN GREEBEL, together with others, did knowingly and
intentionally conspire to devise a scheme and artifice to defraud Retrophin, and to obtain money
and property from Retrophin by means of materially false and fraudulent pretenses,
representations and promises, and for the purpose of executing such scheme and artifice, to
transmit and cause to be transmitted by means of wire communication in interstate and foreign
commerce writings, signs, signals, pictures and sounds, contrary to Title 18, United States Code,
Section 1343.
-27
CRIMINAL FORFEITURE ALLEGATION

AS TO COUNTS ONE THROUGH SEVEN
52.
The United States hereby gives notice to the defendants that, upon their
conviction of any of the offenses charged in Counts One through Seven, the government will
seek forfeiture, in accordance with Title 18, United States Code, Section 981(a)(l)(C) and Title
28, United States Code, Section 2461(c), of any property, real or personal, which constitutes or is
derived from proceeds traceable to any such offenses.
53.
If any of the above-described forfeitable property, as a result of any act or
omission of the defendants:

a.
cannot be located upon the exercise of due diligence;
b.
has been transferred or sold to, or deposited with, a third party;
c.
has been placed beyond the jurisdiction of the court;
d.
has been substantially diminished in value; or
e.
has been commingled with other property which cannot be divided
without difficulty;
it is the intent of the United States, pursuant to Title 21, United States Code, Section 853(p), to
28
seek forfeiture of any other property of the defendants up to the value of the forfeitable property
described in this.forfeiture allegation.
(Title 18, United States Code, Section 98l(a)(l)(C); Title 21, United States Code,
Section 853(p); Title 28, United States Code, Section 246l(c))
A TRUE BILL
L2~:2
roPERSON
ROBERT L. CAPER
UNITED STATES ATTORNEY
EASTERN DISTRICT OF NEW YORK
29
:--k-
:>

1 Main

Uploaded by

Copyright:

Available Formats

1 Main

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

1 Main

Uploaded by

Copyright:

Available Formats

Case 1:15-cr-00637-KAM Document 1 Filed 12/14/15 Page 1 of 29 PageID #: 1

UNITED STATES DISTRICT COURT

(T. 15, U.S.C., 78j(b) and 78ff;

MARTIN SHKRELI and

At all times relevant to this Indictment, unless otherwise indicated: --; ~

THE GRAND JURY CHARGES:

The Defendants and Relevant Entities

The defendant MARTIN SHKRELI was a resident of Brooklyn, New

Case 1:15-cr-00637-KAM Document 1 Filed 12/14/15 Page 2 of 29 PageID #: 2

The defendant EV AN GREEBEL was a resident of Scarsdale, New York,

MSMB Capital was a Delaware limited partnership founded by the

defendant MARTIN SHKRELI and Co-Conspirator 1, an individual whose identity is known to

MSMB Healthcare was a Delaware limited partnership founded by the

Retrophin LLC ("Retrophin LLC") was a Delaware limited liability

Case 1:15-cr-00637-KAM Document 1 Filed 12/14/15 Page 3 of 29 PageID #: 3

Retrophin was a Delaware corporation founded by the defendant

MARTIN SHKRELI in or about 2011. In or about December 2012, Retrophin became a

The Fraudulent Schemes

In or about and between September 2009 and September 2014, the

a scheme to defraud investors and potential investors in MSMB

a scheme to defraud investors and potential investors in MSMB

Healthcare by inducing them to invest in MSMB Healthcare through material misrepresentations

Case 1:15-cr-00637-KAM Document 1 Filed 12/14/15 Page 4 of 29 PageID #: 4

a scheme to defraud Retrophin by misappropriating Retrophin' s

assets through material misrepresentations and omissions in an effort to satisfy SHKRELI' s

The MSMB Capital Hedge Fund Scheme

In or about and between September 2009 and December 2010, the

defendant MARTIN SHKRELI, together with Co-Conspirator 1, in an effort to induce

Case 1:15-cr-00637-KAM Document 1 Filed 12/14/15 Page 5 of 29 PageID #: 5

In approximately December 2010 and January 2011, the defendant

In reliance on the defendant MARTIN SHKRELI's material

misrepresentations and omissions, on or about December 8, 20 I 0, Investor 1 sent $1,000,000 by

Case 1:15-cr-00637-KAM Document 1 Filed 12/14/15 Page 6 of 29 PageID #: 6

On or about February 1, 2011, the defendant MARTIN SHKRELI took a

In furtherance of the scheme of defraud, the defendant MARTIN

Case 1:15-cr-00637-KAM Document 1 Filed 12/14/15 Page 7 of 29 PageID #: 7

The defendant MARTIN SHKRELI, together with Co-Conspirator 1, also

On or about September 5, 2012, the defendant MARTIN SHKRELI, Co-

Case 1:15-cr-00637-KAM Document 1 Filed 12/14/15 Page 8 of 29 PageID #: 8

The MSMB Healthcare Hedge Fund Scheme

Case 1:15-cr-00637-KAM Document 1 Filed 12/14/15 Page 9 of 29 PageID #: 9

SHKRELI' s liability to Merrill Lynch. In sum, thirteen individuals invested a total of

In furtherance of the scheme to defraud, the defendant MARTIN

SHKRELI made material misrepresentations to potential investors about MSMB Healthcare's

The defendant MARTIN SHKRELI also made material misrepresentations

The defendant MARTIN SHKRELI, together with others, also

Case 1:15-cr-00637-KAM Document 1 Filed 12/14/15 Page 10 of 29 PageID #: 10

To achieve this fraudulei:it objective, in or about November 2012, the

defendant MARTIN SHKRELI improperly reclassified a $900,000 equity investment by MSMB

The Retrophin Misappropriation Scheme

The defendants MARTIN SHKRELI and EVAN GREEBEL, together

with others, engaged in a scheme to defraud Retrophin by misappropriating Retrophin' s assets

Case 1:15-cr-00637-KAM Document 1 Filed 12/14/15 Page 11 of 29 PageID #: 11

The Fabricated MSMB Capital Interest

In or about March 2011, the defendant MARTIN SHKRELI valued

As of July 31, 2012, Retrophin LLC's capitalization table, which was

Case 1:15-cr-00637-KAM Document 1 Filed 12/14/15 Page 12 of 29 PageID #: 12

approximately $4.75 million in investments in Retrophin LLC, but no investments by MSMB